Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hikma Pharmaceuticals Plc ADR (OP: HKMPY ) 51.10 -2.07 (-3.90%) Streaming Delayed Price Updated: 3:50 PM EDT, Sep 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 753 Open 52.16 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 53.17 Today's Range 51.10 - 52.16 52wk Range 42.23 - 55.56 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production September 06, 2024 Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. Via Benzinga Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices August 28, 2024 Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... Via Benzinga Performance YTD +12.48% +12.48% 1 Month +0.79% +0.79% 3 Month +1.99% +1.99% 6 Month +5.06% +5.06% 1 Year -3.57% -3.57% More News Read More Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa January 08, 2024 From Guardant Health, Inc. Via Business Wire Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape June 12, 2023 Via Benzinga Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region December 26, 2022 From Junshi Biosciences Via GlobeNewswire Friday Markets News March 25, 2022 Via Talk Markets Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab) August 27, 2021 From Bio-Thera Solutions, Ltd. Via Business Wire Summer Friday June 25, 2021 Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.